Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$5,619
in 1 filing, $6K under 10b5-1 plans

Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Prener Anne −$6K Director sold 4% of stake
Date Insider Transaction Shares Price Value Owned after
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Purchase +94,546 $16.00 $1.5M 1,109,802
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Purchase +105,000 $16.00 $1.7M 1,213,926
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Purchase +43,750 $16.00 $700K 149,262
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series A Preferred Stock −1,363,542 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series A Preferred Stock −663,825 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series A Preferred Stock −737,226 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series B-1 Preferred Stock −169,307 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series B-1 Preferred Stock −82,425 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series B-1 Preferred Stock −91,538 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series B-1 Preferred Stock −68,654 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series C Preferred Stock −163,612 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series C Preferred Stock −88,460 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series C Preferred Stock −79,653 0
2020-04-13 Pontifax Management 4 G.P. (2015) Ltd. 10% owner Conversion · Series C Preferred Stock −36,858 0
2020-04-13 ORBIMED ADVISORS LLC Director Conversion +744,612 744,612
2020-04-13 ORBIMED ADVISORS LLC Director Conversion +148,922 148,922
2020-04-13 ORBIMED ADVISORS LLC Director Purchase +375,200 $16.00 $6.0M 1,119,812
2020-04-13 ORBIMED ADVISORS LLC Director Conversion · Series C Preferred Stock −744,612 0
2020-04-13 ORBIMED ADVISORS LLC Director Conversion · Series C Preferred Stock −148,922 0
2020-04-13 Nussbaum Ran Director Conversion +1,363,542 1,734,395

Page 31 of 36 · 707 trades